Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 over exp |
Therapy | INCB086550 |
Indication/Tumor Type | breast cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 over exp | breast cancer | sensitive | INCB086550 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, INCB086550 decreased CD274 (PD-L1) surface expression and tumor growth in a cell line xenograft model of breast cancer with high CD274 (PD-L1) expression (PMID: 35254416). | 35254416 |
PubMed Id | Reference Title | Details |
---|---|---|
(35254416) | Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor. | Full reference... |